BF
IOVA icon

BOK Financial’s Iovance Biotherapeutics IOVA Stock Holding History

BOK Financial’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,248
Closed -$444K – 918
2022
Q2 		$444K Buy
40,248
+658
+2% +$8.62K 0.01% 695
2022
Q1 		$659K Buy
39,590
+4,843
+14% +$74.9K 0.01% 676
2021
Q4 		$664K Buy
+34,747
New +$765K 0.01% 672

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BOK Financial's IOVA Position: Q3 2022 in Review

BOK Financial sold out of Iovance Biotherapeutics (IOVA) in Q3 2022, closing a stake of 40,248 shares — an estimated $444K sold.

BOK Financial first reported a position in IOVA in Q4 2021 and held it in 3 quarters. The position peaked at $664K in Q4 2021. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

  • BOK Financial reported no remaining Iovance Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • BOK Financial sold 40,248 Iovance Biotherapeutics shares in Q3 2022, an estimated $444K.
  • BOK Financial first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • BOK Financial's Iovance Biotherapeutics position peaked at $664K in Q4 2021.
  • 242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on BOK Financial's 13F filing for Q3 2022, filed 14 Nov 2022.